IL33 and acromesomelic dysplasia 3: IL-33 has been extensively researched in aMDD; interestingly, in contrast to our findings, a recent meta-analysis pointed to decreased levels of IL-33 in plasma of aMDD patients compared to controls [45]; other studies described its neuroprotective functions and positive effects on cognitive outcomes [46, 47].